App-Quantinova.ai

A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

indacaterol

Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma

Sunny Jabbal - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

indacaterol

Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study

Jadwiga Wedzicha - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

salmeterol + fluticasone

Contractile effects of NaV1.5 current in rabbit bronchial smooth muscle

keith Thornbury - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Tetrodotoxin

Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD

Gary Ferguson - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Revefenacin

Clinically-relevant computational model of airway remodelling to design and optimise interventions to treat asthma

Himanshu Kaul - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Case series of long-term macrolide therapy effect on eosinophil count in COPD

Rachelle Asciak - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Differences in attitudes and knowledge of doctors and nurses towards oxygen prescribing in a district general hospital

Syed Fayyaz Hussain - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes

Mark Dransfield - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Umeclidinium

Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study

Jadwiga Wedzicha - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

salmeterol + fluticasone

Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses

David Lipson - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

fluticasone furoate/umeclidinium/vilanterol

Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)

David Bell - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Fluticasone propionate

CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRILOGY study

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

beclometasone dipropionate

Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles

Cedric Van Holsbeke - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

budesonide + formoterol fuma

Plume spray force of three HFA-propelled ICS/LABA combination inhalers

John Tuohy - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics

Carol Astbury - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

AZD 8999

Tools with inhalation technique feedback to improve and maintain pMDI use in asthma patients

Wesam Ammari - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Asthma

N/A

Pressurised metered dose inhalers (pMDIs) with integrated flow rate guidance

Mark Sanders - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Atrovent

Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies

J. Mark FitzGerald - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Filters

45280 Abstracts